Equillium, Inc.
NASDAQ:EQBiotechnology
+$0.05 today
- Market cap
- $90.56M
- Beta
- 1.76
- P/E (TTM)
- -15.3
- EPS (TTM)
- -$0.20
Volume 0.89M
Average 0.60M
EQ Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Equillium, Inc.NASDAQ: EQ
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development declines year over year
Q1 FY2026 research & development of $2.99M fell 49.5% year over year, ahead of the -70.5% change in trailing-twelve-month research & development. Sequentially, it rose 94.7% from the prior quarter. Over 3 fiscal years it compounded at -30.1% a year.
Context
- Research & development increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of -49.5% holds above the trailing-twelve-month pace of -70.5%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 12.84M USD
- Year-over-year change
- -65.7%
- 4-year CAGR
- -16.5%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 12.84M | -65.7% |
| FY2024 | 2024-12-31 | 37.43M | +1.1% |
| FY2023 | 2023-12-31 | 37.04M | -1.4% |
| FY2022 | 2022-12-31 | 37.55M | +42.3% |
| FY2021 | 2021-12-31 | 26.38M | — |
Research & Development vs competitors
How EQ compares with its peers on the latest reported figures
- EQ's LTM Mar 2026 research & development of $9.91M is the 6th highest of the 10 companies compared; the peer median is $16.69M.
- Its year-over-year change of -70.5% is the 9th highest of 10, against a peer median of -18.5%.
- Over three fiscal years its annual growth of -30.1% compares with a peer median of -0.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
OSTXOS Therapies Incorporated | LTM Mar 2026 | $16.37B | +432309.4% | +1606.6% | — |
| LTM Mar 2026 | $83.18M | -24.7% | -0.5% | — | |
| LTM Mar 2026 | $36.03M | +4.0% | -0.7% | 110.1% | |
| LTM Mar 2026 | $21.25M | -43.8% | +8527.1% | 6378.2% | |
| LTM Mar 2026 | $16.69M | -64.4% | -17.8% | — | |
| LTM Mar 2026 | $9.91M | -70.5% | -30.1% | — | |
| LTM Mar 2026 | $8.51M | -76.4% | -55.5% | 12.9% | |
| LTM Mar 2026 | $4.28M | -18.5% | -39.5% | 186.8% | |
| LTM Mar 2026 | $2.57M | +40.4% | +43.0% | — | |
| LTM Mar 2026 | $1.43M | -13.1% | +294.0% | 100.9% | |
| Peer median (excluding EQ) | $16.69M | -18.5% | -0.5% | 110.1% | |
Competitors are the stored peer set for EQ. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 15.76M | 36.08M | 41.1M | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 116K |
| Gross Profit | 0 | 15.76M | 36.08M | 41.1M | (116K) |
| Gross Margin | — | 100.0% | 100.0% | 100.0% | — |
| Research & Development | 26.38M | 37.55M | 37.04M | 37.43M | 12.84M |
| Selling, General & Admin | 11.41M | 17.24M | 13.57M | 11.94M | 10.79M |
| Operating Expenses | 37.79M | 77.84M | 50.61M | 49.36M | 23.63M |
| Depreciation & Amortization | 72K | 118K | 126K | 137K | 116K |
| EBITDA | (37.91M) | (61.26M) | (12.14M) | (7.57M) | (22.28M) |
| EBITDA Margin | — | -388.7% | -33.6% | -18.4% | — |
| Operating Income | (37.79M) | (62.08M) | (14.52M) | (8.27M) | (23.63M) |
| Operating Margin | — | -393.9% | -40.2% | -20.1% | — |
| Interest Income | 57K | 420K | 2.33M | 1.38M | 833K |
| Interest Expense | 1.07M | 1.05M | 491K | 0 | 0 |
| Other Income / Expenses | (1.27M) | (352K) | 1.77M | 563K | 1.24M |
| Income Before Tax | (39.05M) | (62.43M) | (12.76M) | (7.71M) | (22.4M) |
| Pre-Tax Margin | — | -396.1% | -35.3% | -18.8% | — |
| Income Tax Expense | 0 | 0 | 580K | 361K | 0 |
| Net Income | (38.98M) | (62.43M) | (13.34M) | (8.07M) | (22.4M) |
| Net Margin | — | -396.1% | -37.0% | -19.6% | — |
| EPS (Basic) | (1.35) | (3.19) | (0.38) | (0.23) | (0.39) |
| EPS (Diluted) | (1.35) | (3.19) | (0.38) | (0.23) | (0.39) |
| Weighted Avg Shares | 28.81M | 33.73M | 34.73M | 35.36M | 91.88M |
| Weighted Avg Shares (Diluted) | 28.81M | 33.73M | 34.73M | 35.36M | 91.88M |
Equillium, Inc.
NASDAQ:EQ
Intrinsic Alpha fair value
Locked
Current Price
$1.10
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.